Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group

Hamid Sayar, Rebecca Chan, Christie Orschell, Edward M. Chan, Zhangsheng Yu, Daniel Hood, Artur Plett, Zhenyun Yang, Chua Lin Hui, Sarah C. Nabinger, Kristopher J. Kohlbacher, Evan S. West, Amanda Walter, Carol Sampson, Jingwei Wu, Larry Cripe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50mg/m 2 thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX L was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX L and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.

Original languageEnglish
Pages (from-to)1108-1110
Number of pages3
JournalLeukemia Research
Volume35
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Apoptosis
Erythropoiesis
Transferases
Erythropoietin
Anemia
Appointments and Schedules
Bone Marrow
Population
Therapeutics

Keywords

  • Azacitidine
  • MDS
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes : A study of the Hoosier Oncology Group. / Sayar, Hamid; Chan, Rebecca; Orschell, Christie; Chan, Edward M.; Yu, Zhangsheng; Hood, Daniel; Plett, Artur; Yang, Zhenyun; Hui, Chua Lin; Nabinger, Sarah C.; Kohlbacher, Kristopher J.; West, Evan S.; Walter, Amanda; Sampson, Carol; Wu, Jingwei; Cripe, Larry.

In: Leukemia Research, Vol. 35, No. 8, 08.2011, p. 1108-1110.

Research output: Contribution to journalArticle

Sayar, H, Chan, R, Orschell, C, Chan, EM, Yu, Z, Hood, D, Plett, A, Yang, Z, Hui, CL, Nabinger, SC, Kohlbacher, KJ, West, ES, Walter, A, Sampson, C, Wu, J & Cripe, L 2011, 'Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group', Leukemia Research, vol. 35, no. 8, pp. 1108-1110. https://doi.org/10.1016/j.leukres.2011.02.025
Sayar, Hamid ; Chan, Rebecca ; Orschell, Christie ; Chan, Edward M. ; Yu, Zhangsheng ; Hood, Daniel ; Plett, Artur ; Yang, Zhenyun ; Hui, Chua Lin ; Nabinger, Sarah C. ; Kohlbacher, Kristopher J. ; West, Evan S. ; Walter, Amanda ; Sampson, Carol ; Wu, Jingwei ; Cripe, Larry. / Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes : A study of the Hoosier Oncology Group. In: Leukemia Research. 2011 ; Vol. 35, No. 8. pp. 1108-1110.
@article{a736e153efc94855a70d13cf53f5a7af,
title = "Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group",
abstract = "Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10{\%} marrow blasts received azacitidine 50mg/m 2 thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43{\%} did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX L was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX L and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.",
keywords = "Azacitidine, MDS, Myelodysplastic syndromes",
author = "Hamid Sayar and Rebecca Chan and Christie Orschell and Chan, {Edward M.} and Zhangsheng Yu and Daniel Hood and Artur Plett and Zhenyun Yang and Hui, {Chua Lin} and Nabinger, {Sarah C.} and Kohlbacher, {Kristopher J.} and West, {Evan S.} and Amanda Walter and Carol Sampson and Jingwei Wu and Larry Cripe",
year = "2011",
month = "8",
doi = "10.1016/j.leukres.2011.02.025",
language = "English",
volume = "35",
pages = "1108--1110",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes

T2 - A study of the Hoosier Oncology Group

AU - Sayar, Hamid

AU - Chan, Rebecca

AU - Orschell, Christie

AU - Chan, Edward M.

AU - Yu, Zhangsheng

AU - Hood, Daniel

AU - Plett, Artur

AU - Yang, Zhenyun

AU - Hui, Chua Lin

AU - Nabinger, Sarah C.

AU - Kohlbacher, Kristopher J.

AU - West, Evan S.

AU - Walter, Amanda

AU - Sampson, Carol

AU - Wu, Jingwei

AU - Cripe, Larry

PY - 2011/8

Y1 - 2011/8

N2 - Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50mg/m 2 thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX L was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX L and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.

AB - Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50mg/m 2 thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX L was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX L and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.

KW - Azacitidine

KW - MDS

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=79960265161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960265161&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.02.025

DO - 10.1016/j.leukres.2011.02.025

M3 - Article

C2 - 21420732

AN - SCOPUS:79960265161

VL - 35

SP - 1108

EP - 1110

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -